孕期接种Tdap疫苗的患者反应
这是一项2014年5月至2016年3月开展的前瞻性观察研究,评估孕期接种Tdap疫苗后1-7天内的主动报告反应。737名患者中496人(67%,95%CI 64-71%)出现至少1种反应,187人(25%,95%CI 22-29%)出现2种及以上反应;24人(3%,95%CI 2-5%)表示因本次妊娠反应不会在后续妊娠中再次接种。
要点
- 孕期接种Tdap后2/3患者出现至少1种反应,1/4出现2种及以上反应。
- 多数患者表示疫苗接种可耐受,但3%因反应拒绝后续妊娠再次接种。
- 作者认为若进一步研究显示相似结果,或需评估孕期使用百日咳单价疫苗。
核心结论
- 孕期接种Tdap后母体反应常见,约三分之二的研究人群出现至少1种反应。
- 部分患者可能因本次妊娠的反应而拒绝在后续妊娠中再次接种,这值得关注。
- 作者认为若进一步研究显示相似结果,或需评估孕期使用百日咳单价疫苗。
研究设计与样本
- 前瞻性观察研究,于2014年5月至2016年3月开展。
- 在接种Tdap疫苗后1-7天内主动收集患者反应。
- 共评估737名患者。
主要发现
- 496名患者(67%,95%CI 64-71%)出现至少1种接种反应。
- 187名患者(25%,95%CI 22-29%)出现2种及以上反应。
- 24名患者(3%,95%CI 2-5%)表示因本次妊娠接种反应不会在后续妊娠中再次接种Tdap。
- 多数患者表示该疫苗接种可耐受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current obstetrical recommendation is to routinely administer the tetanus, diphtheria, and acellular pertussis (Tdap) vaccination during every pregnancy regardless of a patient's prior history. There are minimal data that have prospectively evaluated solicited patient response to this treatment plan. The study objective was to evaluate patient reaction following receipt of Tdap vaccination during pregnancy. METHODS: This was a prospective observational study conducted from May 2014 through March 2016. The study design involved solicited patient reaction within 1-7days after the administration of the Tdap vaccine. Data collected included pain or soreness, swelling, and/or redness at the injection site, as well as, fever and generalized body aches. Statistical analysis involved simple percentages with Poisson binomial 95% confidence intervals with Chi-square and Fisher's exact comparisons where appropriate. RESULTS: A total of 737 patients were evaluated and 496 (67%, 95% Confidence Interval [CI] 64-71%) were found to have at least 1 reaction to the vaccination and 187 (25%, 95% CI 22-29%) had 2 reactions or more. Overall, the majority of patients stated that the vaccination was tolerated. However, 24 (3%, 95% CI 2-5%) of the study population stated that they would not accept receipt of Tdap in a subsequent pregnancy because of the response that occurred in the current pregnancy. CONCLUSION: These data demonstrate that maternal reactions following receipt of Tdap are common (two-thirds of the study population). A potential concern is the finding that some patients might refuse a repeat vaccination in a subsequent pregnancy due to these reactions. If further research reveals similar findings, a pertussis only vaccine for pregnant patients might need to be evaluated.
引用
- Perry J, Towers CV, Weitz B, et al. Patient reaction to Tdap vaccination in pregnancy. Vaccine. 2017. PMID: 28456527. doi:10.1016/j.vaccine.2017.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。